MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

Agilent's MAGE-A4 IHC 1F9 pharmDx Gets FDA Approval as Diagnostic Tool for New TCR T-Cell Therapy

NextEdge Admin

03 Aug 2024

2 min 3 sec

Agilent Technologies Inc. has announced that it has received FDA approval for its MAGE-A4 IHC 1F9 pharmDx (SK032) as a diagnostic tool to identify patients with synovial sarcoma who may be eligible for treatment with TECELRA® (afamitresgene autoleucel, also known as afami-cel or ADP-A2M4), a MAGE-A4-directed engineered TCR T-Cell therapy.

MAGE-A4, a cancer-testis antigen, is overexpressed in various cancers, including synovial sarcoma. The MAGE-A4 IHC 1F9 pharmDx is an immunohistochemistry (IHC) assay designed to detect MAGE-A4 expression in formalin-fixed paraffin-embedded (FFPE) synovial sarcoma tissue. Detection of MAGE-A4 in synovial sarcoma serves as a biomarker indicating potential eligibility for TECELRA® treatment. This marks MAGE-A4 IHC 1F9 pharmDx as the first in vitro diagnostic (IVD) test for MAGE-A4 available on the market.

Lou Welebob, Agilent’s vice president and general manager of the Pathology Division, emphasized that MAGE-A4's significant role in cancer research highlights its potential as a therapeutic target. The FDA's approval enhances treatment options for patients with synovial sarcoma and underscores Agilent’s leadership in developing companion diagnostics for innovative cancer therapies.

TECELRA® is an FDA-approved prescription therapy for advanced MAGE-A4 positive synovial sarcoma in adults with specific HLA types who have undergone prior chemotherapy. It represents the first FDA-approved engineered TCR T-Cell therapy for solid tumor cancers.